Anadys Forms Collaboration With Gilead

gilead, Inc. and Gilead Sciences, Inc. have entered into a collaboration to discover novel antiviral compounds.

As part of the collaboration agreement, Anadys will design, configure and run uHTS-ATLAS screens against a key viral target selected by Gilead.

This agreement leverages Anadys’ powerful ability to screen for small molecules that bind to proteins that are difficult to screen using conventional methods.

Under the terms of the agreement, Anadys will design and run uHTS-ATLAS assays against Gilead’s compound collection.

Gilead will have exclusive rights to develop and commercialize any products resulting from compounds discovered in the collaboration.

“We are very pleased to collaborate with Gilead on this important and challenging viral target,” said Dr. Steve Worland, Chief Scientific Officer of Anadys.

“Gilead is viewed as one of the premier organizations involved in antiviral research, and their decision to employ uHTS- ATLAS is important validation for our technology. It also highlights one of the key advantages of our technology in that we can screen targets that have traditionally been a challenge.”

“The collaboration with Gilead further illustrates Anadys’ overall commitment to broadening our efforts in the antiviral therapeutic area,” said Michael Kamdar, Vice President of Corporate Development and Strategy for Anadys.

“We look forward to building a long term relationship with Gilead, which has a strong record of developing and commercializing antiviral therapies.” Anadys Pharmaceuticals, Inc. is a new generation drug discovery company committed to applying an integrated approach that combines biology and chemistry to develop new small molecule therapeutics.

Gilead Sciences is a biopharmaceutical company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials.


Generic drug giant Dragon Pharma is offering: